Why the study?
Does intracoronary verapamil administration improve the 'no-reflow' phenomenon in patients undergoing percutaneous coronary intervention?
Does intracoronary verapamil administration improve the 'no-reflow' phenomenon in patients undergoing percutaneous coronary intervention?
Intracoronary verapamil is an effective treatment for the no-reflow phenomenon during percutaneous coronary intervention, suggesting microvascular spasm as a potential etiology.
Answers are grounded in this paper and cite their sources.
May support verapamil for no-reflow in PCI; leaves open randomized confirmation of efficacy and microvascular spasm mechanism.
The no-reflow phenomenon--reduction in distal flow without apparent dissection or distal embolization--occurs in 2% of coronary interventions. It generally responds promptly to intracoronary verapamil administration, suggesting that distal microvascular spasm may be its etiology.
No takes yet. Share an insight, caveat, or question.
Piana et al. (1994) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: